Application Note: Comparison of Anti-TNFα Monoclonal Antibody Biosimilars
Authors: Kirsty McBain, Daryl Cole, Stuart Knowling and Nicola Bevan
Application Note: Combining Binding and Functional Analyses for Comparison of Anti-TNFα Monoclonal Antibody Biosimilars
Biosimilars are biological medicines which are produced to be highly similar in structure and function to an already approved product. They can be released after patent expiration of the reference product on which they are based. Since biosimilars are based upon an existing product, the cost of their development is much lower than the original, resulting in a drug that can be marketed at a lower price.
Biosimilars are now available as treatments in a range of therapeutic areas, from inflammatory diseases to cancers, such as monoclonal antibody (mAb) biosimilars. Adalimumab (Humira®) is a TNFα-targeting mAb that is used to treat a wide range of inflammatory diseases.
In this application note, the iQue® Advanced Flow Cytometry Platform and Octet® Biolayer Interferometry (BLI) System, have been used to compare the binding and function of anti-TNFα (adalimumab) mAbs. The iQue® platform was used to perform high-throughput measurement of mAb binding to live cells, and quantification of in vitro functional activity. These data were complemented with real-time assessment of mAb binding kinetics to the TNFα target and FcγRIIIa receptor CD16a V176 using the Octet® BLI System.
- Document type: Application Note
- Page count: 14
- Read time: 20 minutes
Application Note Sections include details of:
- Target Antigen Binding
- Live-Cell Binding
- Inhibition of TNFα-Induced Apoptosis
- Complement-Dependent Cellular Cytotoxicity (CDC)
- Antibody-Dependent Cellular Cytotoxicity (ADCC)
